4-Demethoxydaunorubicin (Idarubicin) in Relapsed and Refractory Acute Myeloid Leukemia

Despite the progress in the treatment of adult acute myeloid leukemia (AML), most of the patients achieving complete remission (CR) with induction chemotherapy will relapse within 2 years. Therefore, there is an urgent need for new developments in the treatment of adult AML. The application of new chemotherapeutic drugs may be one way to achieve success. Because anthracyclines are highly effective in the treatment of AML, it may be possible that anthracycline analogues will increase the therapeutic results.